We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Trinity Biotech PLC | NASDAQ:TRIB | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.03 | 1.69% | 1.81 | 1.78 | 1.83 | 1.81 | 1.78 | 1.81 | 3,808 | 16:53:10 |
From Apr 2019 to Apr 2024
Interested parties can access the call by dialing:
| USA: | 1-888-243-4451 |
| International: | 1-412-542-4135 |
| Conference ID #: | 10064828 |
A simultaneous webcast of the call can be accessed at: http://www.videonewswire.com/event.asp?id=102224
A replay of the call can be accessed until May 7, 2015 by dialing:
| USA: | 1-877-344-7529 |
| International: | 1-412-317-0088 |
| Conference ID #: | 10064828 |
The webcast of the call will be available for 30 days at: http://www.videonewswire.com/event.asp?id=102224
About Trinity Biotech plc
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
Hot Features
Premium
CONTACT: Kevin Tansley
Trinity Biotech plc
(353)-1-2769800
E-mail: kevin.tansley@trinitybiotech.com
Joe Diaz, Joe Dorame and Robert Blum
Lytham Partners, LLC
Investor Relations
602-889-9700
1 Year Trinity Biotech Chart |
1 Month Trinity Biotech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
